Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting
timothy sykes logo

Stock News

BriaCell’s Unexpected Stock Rally: Buy or Hold?

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
Updated 4/25/2025, 9:18 am ET 5 min read
BriaCell’s Unexpected Stock Rally: Buy or Hold? Thumbnail

BriaCell Therapeutics Corp. stocks have been trading down by -20.9 percent amid recent news impacting market sentiment.

Initial Market Reaction: Recent Developments

  • BriaCell, a company deeply involved in advancing breast cancer treatment, made a bold move by filing to offer 2.33M common shares along with warrants, with ThinkEquity orchestrating the underwriting.

  • The secondary share offering of BriaCell was priced at $4.50 each, which was well below its previous closing price of $6.03. The offering’s volume increased to a massive 3.07M shares.

Candlestick Chart

Live Update At 09:18:20 EST: On Friday, April 25, 2025 BriaCell Therapeutics Corp. stock [NASDAQ: BCTX] is trending down by -20.9%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Recent Market Moves: Understanding Key Metrics

Trading can be a daunting pursuit, particularly for those new to the stock market. The thrill of potential profit can often lead traders to make impulsive decisions. However, successful trading requires careful analysis, disciplined execution, and the ability to walk away when necessary. As millionaire penny stock trader and teacher Tim Sykes says, “It’s better to go home at zero than to go home in the red.” This mindset encourages traders to prioritize risk management and accept small losses rather than risking larger, potentially devastating losses. By learning to embrace this approach, traders can cultivate a more sustainable and successful trading practice.

In recent trading days, BriaCell’s stock performance has been nothing short of intriguing. The stock opened at $9.35 before sliding to close at $6.03 on Apr 24, 2025. This marks a drastic drop which is largely attributed to the pricing of their secondary offering at $4.50. Companies sometimes lower their stock price to make new shares more appealing, a tactic often resulting in temporary stock volatility.

More Breaking News

BriaCell’s financial strategies have painted a complex picture. The company’s enterprise value, sitting at around $49M, reflects its current market position, while the price-to-book ratio at 4.51 suggests potential overvaluation based on current assets. The total debt-to-equity ratio is refreshingly zero, showcasing strong financial health by traditional measures. However, the concerning aspect is net income from ongoing operations showing a substantial loss. Revenue is still struggling to gain traction but remains supported by strategic investments and innovations in medical research.

Financial Insights: Earnings and Strategy

BriaCell’s latest financial report also showed a net loss exceeding $6M for its last reporting quarter, emphasizing the struggle in stabilizing its operational cash flow at present. Revenue wasn’t strong enough to cover expenses, due in part to hefty research costs which are common in the biopharma world. The company, however, managed to raise over $4.68M through issuing new stock, illustrating a reliance on shareholder funding amid its developmental stages.

A silver lining remains in its key financial strength metrics. With no long-term debt encumbering the company, BriaCell is positioned well to continue focusing its resources on advancing its promising therapeutic candidates. Operating cash outflow is sizeable, but this mirrors the investment needed to catalyze growth in cutting-edge medical innovations.

Strategic Considerations and Market Outlook

The current news surrounding BriaCell’s share offering deserves a deeper dive. For would-be traders and market followers, the company’s move to increase its share offering signifies bolstered confidence in raising capital for their ambitious goals. By assessing how these actions could refine the company’s financial foundation, there’s potential for value growth if their breast cancer treatment candidates prove successful.

Market sentiment currently juggles optimism attached to medical breakthroughs with caution related to financial metrics. Stocks in biotech present formidable risks; traders engage with an eye toward long-term breakthroughs. Patient shareholders participate not just in monetary trading, but in supporting life-changing technological strides. As millionaire penny stock trader and teacher Tim Sykes, says, “You must adapt to the market; the market will not adapt to you.” This serves as a poignant reminder for traders to stay flexible and responsive to market dynamics.

In conclusion, BriaCell’s stock fluctuations offer intrigue both for strategic traders and hopeful participants. The company’s active efforts in cancer therapy position it as a unique player in the life sciences. The pivotal message remains: as this odyssey transitions from potential dips to possible recovery and innovation, maintaining strategic patience could well be the key, aligning financial returns with significant scientific advancements.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM

We use cookies to provide you with the best online experience. If you continue browsing, we consider that you accept our Cookie Policy , and also agree to the terms of our Privacy Policy and Terms of Use.

notification icon
Subscribe to receive notifications